Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

CJC Dosage: Research Protocol Explanation (Not Medical Advice)

Back to library
peptide

CJC Dosage: Research Protocol Explanation (Not Medical Advice)

15 min read
Compound Guide
Growth Hormone Research
Research Protocol
GHRH Analogue
Last Updated: May 2026

The search term “CJC dosage” is one of the most commonly entered queries in the GH peptide research space — and it is almost always entered by someone looking for information that no article should provide. CJC-1295 (specifically the DAC version, CJC-1295+DAC) is a GHRH (Growth Hormone Releasing Hormone) analogue — a compound studied in human clinical trials for its ability to sustain growth hormone and IGF-1 elevation over extended periods via an albumin-binding pharmacokinetic modification. What doses were studied in those trials, what those trials found, and what distinguishes CJC-1295+DAC from its shorter-acting variant (Mod GRF 1-29, CJC-1295 without DAC) — that is what this article covers. Actual dosing for any individual requires a licensed medical professional and is outside the scope of any research supplier.

This article explains the pharmacology of CJC-1295+DAC, what published research (including the only published human trial, Alba et al. 2006) examined in terms of dose ranges, the critical distinction between CJC-1295 with and without DAC, and the research context in which CJC-1295 is studied alongside GHRP compounds such as GHRP-2 and Ipamorelin. For research purposes only. Not for human consumption.

Key Takeaways

  • CJC-1295 is a GHRH (Growth Hormone Releasing Hormone) analogue — it stimulates the pituitary to release GH by activating the GHRH receptor (GHRHR), a fundamentally different mechanism from GHRP compounds like GHRP-2 or Ipamorelin which act via the ghrelin receptor (GHS-R1a).
  • The DAC (Drug Affinity Complex) modification in CJC-1295+DAC (CAS: 863288-34-0) extends plasma half-life from approximately 30 minutes (Mod GRF 1-29, without DAC) to a functional half-life of up to 8 days by binding reversibly to endogenous albumin — a critical pharmacokinetic distinction.
  • The only published human trial — Alba M et al. (2006, J Clin Endocrinol Metab) — studied single doses of 30 µg/kg and 60 µg/kg SC in 21 healthy adults; both doses produced sustained GH and IGF-1 elevation for 1–2 weeks with mild adverse events (transient flushing, injection site reactions).
  • CJC-1295 and GHRP compounds (GHRP-2, Ipamorelin) act via complementary but mechanistically distinct receptor pathways — making them subjects of combined research design; Pure Grade Labs supplies both the CJC-1295+DAC component and the GHRP compounds as separate research-grade materials.
  • “CJC dosage” as a search query requires medical guidance, not an article. What this article covers is the dose ranges examined in published research trials — not a prescriptive recommendation for any individual or application.
~8 days
Functional half-life of CJC-1295+DAC via albumin binding (vs ~30 min for Mod GRF 1-29 without DAC) — reported in Jette L et al. (2005, Endocrinology)
4–6×
GH increase above baseline in the Alba et al. (2006) human trial at both 30 µg/kg and 60 µg/kg SC doses — sustained over 1–2 weeks post-administration
2×
IGF-1 increase (up to 2-fold above baseline) observed in the Alba et al. (2006) trial following a single CJC-1295 (DAC) dose in healthy adults
3,647 Da
Molecular weight of CJC-1295 (without DAC / Mod GRF 1-29); CJC-1295+DAC is approximately 3,800 Da due to the DAC albumin-binding modification

Source CJC-1295+DAC for Research

HPLC-verified purity. Batch-specific COA. CJC-1295+DAC 10mg — research-grade standard. Not for human consumption.

View CJC-1295+DAC 10mg →

What Is CJC-1295? GHRH Analogue Mechanism Explained

CJC-1295 — and by shorthand “CJC” or “CJC1295” in research and online discussions — refers to a synthetic analogue of GHRH (Growth Hormone Releasing Hormone), the endogenous 44-amino acid peptide secreted by the hypothalamus that stimulates the anterior pituitary to release growth hormone (GH). Native GHRH binds to the GHRH receptor (GHRHR, also called the growth hormone releasing hormone receptor) on somatotroph cells in the anterior pituitary, activating adenylyl cyclase and cAMP-dependent pathways that culminate in GH secretion.

Native GHRH is pharmacologically limited by very rapid proteolytic cleavage — primarily by dipeptidylpeptidase IV (DPP-IV) and other plasma enzymes — resulting in a plasma half-life of approximately 7 minutes. This short half-life limits its practical utility as a research tool in sustained GH-axis studies. Mod GRF 1-29 (also referred to as CJC-1295 without DAC) was an early modification — a 29-amino acid truncated GHRH analogue with four amino acid substitutions to improve DPP-IV resistance, extending half-life to approximately 30 minutes. The subsequent addition of the Drug Affinity Complex (DAC) modification — a lysine-based albumin-binding linker — produced what is formally designated CJC-1295 with DAC (CAS: 863288-34-0), the compound available from Pure Grade Labs.

This GHRH-receptor mechanism is distinct from how GHRP compounds work. GHRP-2 and Ipamorelin activate the ghrelin receptor (GHS-R1a), triggering GH release via an intracellular calcium and protein kinase C pathway. CJC-1295 targets the GHRHR, activating cAMP/PKA pathways. These two receptor systems are complementary — which is precisely why CJC-1295+DAC and GHRP compounds are frequently studied in combination.

CJC-1295 With DAC vs Without DAC (Mod GRF 1-29): The Research-Critical Distinction

This is the most consequential distinction in CJC dosage research discussions — and it is frequently collapsed or confused in online sources. CJC-1295 exists in two pharmacologically distinct forms:

CJC-1295 Without DAC (Mod GRF 1-29)

Mod GRF 1-29 is the 29-amino acid GHRH fragment with four substitution modifications (Ala, Val, Gly, Ser replacements at key DPP-IV cleavage sites) that improve stability without conferring albumin binding. Plasma half-life is approximately 15–30 minutes. The pharmacokinetic profile mimics a pulse — administration produces a brief, sharp GH release pulse that decays within the hour. This makes Mod GRF 1-29 a research tool for studying acute, pulsatile GHRH-mediated GH release, and it is typically studied in combination with short-acting GHS-R1a agonists (such as GHRP-2 or Ipamorelin) to produce coordinated, acute GH pulses.

CJC-1295+DAC (Drug Affinity Complex)

The DAC modification adds a maleimidoproprionic acid-lysine linker (the Drug Affinity Complex) to the Mod GRF 1-29 backbone, which covalently and reversibly binds to Cys-34 of endogenous serum albumin after subcutaneous administration. This albumin binding effectively turns the peptide into a long-acting depot: it is slowly released from albumin as free peptide, then rebinds, resulting in a functional half-life of approximately 5–8 days as measured in animal and human studies. A single administration of CJC-1295+DAC therefore produces a sustained, prolonged elevation in GH and IGF-1 rather than a brief pulse — a fundamentally different pharmacodynamic profile from Mod GRF 1-29.

The foundational pharmacokinetic characterisation of CJC-1295+DAC was published by Jette L et al. (2005, Endocrinology) in rat and primate models, demonstrating the extended GH and IGF-1 elevation following single-dose administration. This paved the way for the first human trial in 2006.

Pure Grade Labs supplies the DAC version: CJC-1295+DAC 10mg. Researchers should confirm which variant they require before sourcing — the pharmacokinetic profiles are not interchangeable and research protocols will differ accordingly.

CJC-1295+DAC vs Mod GRF 1-29 — Key Parameters

Parameter CJC-1295+DAC Mod GRF 1-29 (No DAC)
CAS Number 863288-34-0 863288-34-0 (same backbone; DAC-free analogue varies by source)
Molecular Weight ~3,800 Da (DAC modification adds albumin-binding lysine linker) 3,647.1 Da
Receptor Target GHRHR (GHRH receptor) GHRHR (GHRH receptor)
Plasma Half-Life ~5–8 days (albumin-bound depot) ~15–30 minutes
GH Release Profile Sustained, prolonged elevation Acute, pulsatile
Human Trial Data Alba M et al. (2006, JCEM) — single dose SC study in 21 adults Limited formal human trial data
Research Application Sustained GH/IGF-1 axis studies, chronic GH elevation models Acute pulsatile GH studies, co-administration with GHRP for pulse research
Available from Pure Grade Labs Yes — CJC-1295+DAC 10mg Not currently listed separately

What Human Research Has Examined: Alba et al. (2006)

The primary published human trial of CJC-1295 (DAC version) is Alba M et al. (2006), published in the Journal of Clinical Endocrinology and Metabolism. This was a Phase I/II, randomised, double-blind, placebo-controlled dose-escalation study in 21 healthy adult subjects. The trial examined single subcutaneous doses of 30 µg/kg and 60 µg/kg — these are the dose ranges that this trial studied under controlled clinical conditions, which is the appropriate framing for reporting CJC dosage data in a research context.

Key findings from Alba et al. (2006):

  • GH elevation: Both 30 µg/kg and 60 µg/kg doses produced approximately 4–6-fold increases in mean GH concentration above baseline. Crucially, these elevations were sustained for 1–2 weeks following a single dose — a direct consequence of the DAC albumin-binding pharmacokinetics.
  • IGF-1 elevation: IGF-1 (insulin-like growth factor 1, the downstream mediator of GH action in peripheral tissues) increased up to 2-fold above baseline and remained elevated for the same 1–2 week window.
  • Adverse event profile: All reported adverse events were mild and transient. The most common were transient facial flushing (a known vasodilatory effect associated with GH-axis activation) and injection site reactions. No serious adverse events were reported in this trial at the doses examined.
  • Duration of effect: The extended duration of GH and IGF-1 elevation from a single dose was the key pharmacodynamic finding — demonstrating that the DAC modification successfully converted GHRH agonism from an acute, pulsatile stimulus into a sustained, prolonged GH secretagogue effect.

This trial was conducted in a controlled clinical setting with medical supervision, dose escalation protocols, and safety monitoring infrastructure. The dose ranges examined in this trial (30–60 µg/kg) are reported here for scientific accuracy and context — they do not constitute prescriptive guidance for any individual, and translation from a controlled Phase I/II context to any other setting requires clinical oversight that falls entirely outside the scope of a research supplier or this article.

Why “CJC Dosage” Questions Require a Doctor, Not an Article

Searches for “CJC dosage” or “CJC-1295 dosage” typically come from individuals seeking practical guidance — and this is precisely why the honest answer is: that question requires a licensed medical professional with access to the individual’s complete clinical picture, not a search result or an article from a research supplier.

CJC-1295+DAC acts on the GH axis — a hormonally regulated system with feedback mechanisms involving somatostatin, ghrelin, IGF-1, and downstream effects on glucose metabolism, tissue growth, and cellular proliferation. The appropriate use of any GHRH analogue in a clinical or research context requires:

  • Baseline measurement of GH, IGF-1, and related endocrine markers
  • Assessment of individual health status, contraindications, and concurrent medications
  • Appropriate protocol design with defined endpoints and monitoring parameters
  • Professional oversight for adverse event recognition and management
  • Regulatory compliance with applicable jurisdiction (CJC-1295 is not a licensed medicine in the UK and is sold strictly as a research chemical under HMR 2012)

Pure Grade Labs supplies CJC-1295+DAC as a research-grade compound for laboratory research purposes. This is not a clinical supply channel and cannot provide, imply, or substitute for medical guidance on dosing.

CJC-1295+DAC in Research Combination with GHRP Compounds

One of the most well-characterised research designs in GH-axis pharmacology involves the concurrent administration of a GHRH analogue (CJC-1295+DAC) with a GHS-R1a agonist (such as GHRP-2 or Ipamorelin). The rationale is mechanistic: these two receptor pathways — GHRHR and GHS-R1a — converge on overlapping but non-identical intracellular signalling cascades within somatotroph cells, and their simultaneous activation produces synergistic GH release that substantially exceeds what either compound achieves alone.

The GHRHR pathway (activated by CJC-1295+DAC) primarily signals through adenylyl cyclase → cAMP → PKA → increased GH gene expression and vesicle release. The GHS-R1a pathway (activated by GHRP-2 or Ipamorelin) primarily signals through phospholipase C → IP3 → intracellular Ca²⁺ release. The convergence of cAMP/PKA signalling and elevated intracellular calcium on the same somatotroph cells produces a GH pulse that is pharmacologically amplified beyond what either individual receptor activation achieves.

This mechanistic synergy has been demonstrated in preclinical models and forms the basis for the GH Optimisation Research Combination available from Pure Grade Labs — which pairs CJC-1295+DAC with GHRP-2 as a matched research-grade supply of complementary compounds.

In published research designs, GHRP-2 is used alongside CJC-1295 to investigate how combined GHRHR + GHS-R1a co-activation affects GH pulse amplitude, pulsatility, and downstream IGF-1 responses. Ipamorelin is used in similar designs where the research question requires isolating GHS-R1a-specific contributions without the cortisol and prolactin co-stimulation that GHRP-2 introduces. The choice between GHRP-2 and Ipamorelin as the GHS-R1a component of a CJC-1295 research design therefore depends on whether the protocol needs to account for cortisol/prolactin effects or isolate GH axis activity specifically.

GH Optimisation Research Combination

CJC-1295+DAC paired with GHRP-2 — complementary GHRH + GHS-R1a receptor activation. Research-grade. HPLC-verified. Not for human consumption.

View GH Optimisation Research Combination →

Research Applications of CJC-1295+DAC

CJC-1295+DAC is used in preclinical and translational research across several areas of GH-axis biology. The extended pharmacokinetic profile — producing sustained GH and IGF-1 elevation from infrequent dosing — makes it particularly useful for chronic or longer-duration study designs that would otherwise require repeated daily administration of a short-acting GHRH analogue.

GH Axis Characterisation and IGF-1 Regulation

The primary research application of CJC-1295+DAC is in studies examining how chronic GH elevation — mediated through GHRHR activation rather than exogenous rhGH — affects downstream IGF-1 production, negative feedback regulation (somatostatin responses, GH receptor downregulation), and tissue-level IGF-1 signalling. The albumin-binding mechanism provides a pharmacological tool for sustaining GH-axis activation that mirrors the kind of prolonged GH secretion seen in pathological GH excess states, making it useful for mechanistic studies.

Tissue Repair and Anabolic Signalling Research

IGF-1 is a central anabolic signalling molecule with established roles in muscle protein synthesis, skeletal tissue remodelling, and wound healing cascade modulation. Research models studying the anabolic effects of GH-axis activation use CJC-1295+DAC as a tool to sustain elevated IGF-1 in animal models, examining downstream effects on muscle hypertrophy markers, bone density parameters, and tissue repair kinetics. This is preclinical research in controlled laboratory settings — not a clinical application.

GH Deficiency Models

Animal models of GH deficiency (hypopituitary rodent models, aged animal models with diminished GH pulsatility) use CJC-1295+DAC to restore GH-axis activity and examine whether restoring GH/IGF-1 levels normalises downstream metabolic and structural parameters — providing mechanistic data on the biological role of the GH axis in ageing biology and metabolic regulation.

A laboratory investigating the GH-axis effects of age-related somatotroph decline faces a design challenge: daily administration of a short-acting GHRH analogue would require frequent interventions that confound stress response data. The researcher selects CJC-1295+DAC — single subcutaneous administration twice weekly — to maintain sustained GH and IGF-1 elevation throughout a 12-week observation period, minimising handling stress and allowing clean measurement of downstream anabolic and metabolic endpoints without daily dosing interference. The DAC modification converts what would otherwise be a pharmacokinetic limitation into a research advantage.

Frequently Asked Questions — CJC Dosage and Research Protocol

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 without DAC (Mod GRF 1-29) has a plasma half-life of approximately 15–30 minutes and produces an acute, pulsatile GH release. CJC-1295 with DAC (available here) has a functional half-life of approximately 5–8 days due to its albumin-binding Drug Affinity Complex modification, producing sustained GH and IGF-1 elevation from infrequent dosing. The two compounds have different pharmacokinetic profiles, different research applications, and should not be treated as interchangeable in protocol design.

What doses were studied in the Alba et al. (2006) human trial?

Alba M et al. (2006, J Clin Endocrinol Metab) examined single subcutaneous doses of 30 µg/kg and 60 µg/kg of CJC-1295 (DAC version) in 21 healthy adult subjects. These doses are reported here for scientific accuracy as documented in published literature. They do not constitute prescriptive guidance — any application of CJC-1295 in a clinical setting requires medical supervision and is outside the scope of a research supplier.

How does CJC-1295+DAC differ mechanistically from GHRP-2 or Ipamorelin?

CJC-1295+DAC activates the GHRH receptor (GHRHR) on somatotroph cells via cAMP/PKA pathways. GHRP-2 and Ipamorelin activate the ghrelin receptor (GHS-R1a) via phospholipase C / intracellular calcium pathways. These two pathways are mechanistically distinct but synergistic — concurrent activation of both receptors on the same somatotroph produces GH release that exceeds what either compound achieves alone, which is the basis for combined GHRH + GHRP research designs.

Is CJC-1295 legal in the UK?

CJC-1295 is not a licensed medicine in the UK and is not listed under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. It is legal to supply and purchase as a research chemical under the Human Medicines Regulations 2012 (HMR 2012), provided it is sold for research purposes and not for human use. Pure Grade Labs supplies CJC-1295+DAC strictly as a research compound — not for human consumption.

What is the CJC1295 dosage used in the GH Optimisation Research Combination?

Pure Grade Labs does not prescribe or recommend dosing. The GH Optimisation Research Combination supplies research-grade CJC-1295+DAC and GHRP-2 as matched research materials — researchers design their own protocols based on published literature, institutional guidelines, and the requirements of their specific research question. Published preclinical and clinical studies referenced in this article provide data on dose ranges examined under controlled conditions.

What is the molecular weight and CAS number of CJC-1295+DAC?

CJC-1295 with DAC has CAS number 863288-34-0. The molecular weight of CJC-1295 without the DAC modification (Mod GRF 1-29 backbone) is 3,647.1 Da. The DAC modification (maleimidoproprionic acid-lysine albumin-binding linker) adds additional mass, bringing the full CJC-1295+DAC molecular weight to approximately 3,800 Da.

Research-Grade CJC-1295+DAC — HPLC-Verified

Batch-specific COA. 10mg per vial. Sourced for laboratory research. Not for human consumption. Ships from UK.

Source CJC-1295+DAC 10mg →

Summary

CJC-1295 — specifically the DAC-modified version (CJC-1295+DAC, CAS: 863288-34-0) — is a long-acting GHRH analogue with a demonstrated ability to sustain GH and IGF-1 elevation over approximately 1–2 weeks from a single administration, as shown in the Alba et al. (2006) human trial. Its mechanism — GHRHR activation on pituitary somatotrophs via cAMP/PKA pathways — is complementary to and synergistic with GHS-R1a agonists such as GHRP-2 and Ipamorelin, making combined GHRH + GHRP research designs a well-characterised area of GH pharmacology research.

The distinction between CJC-1295+DAC and Mod GRF 1-29 (CJC-1295 without DAC) is pharmacokinetically fundamental: a half-life of 5–8 days versus 15–30 minutes produces entirely different pharmacodynamic profiles and requires different research protocol design. Researchers sourcing CJC-1295 should confirm which variant they require.

Searches for “CJC dosage” or “CJC-1295 dosage” for individual human use require medical guidance — not a supplier article. What this article has documented is what the published literature has studied, in what controlled contexts, at what dose ranges, and with what observed outcomes. That is the appropriate scope for a research-grade compound supplier to address.

References

  1. Alba M, Fintini D, Salvatori R, et al. Effects of long-acting growth hormone-releasing hormone analog (CJC-1295) on GH and IGF-I secretion in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1334
  2. Jette L, Léger R, Bhatt D, et al. Growth hormone-releasing peptide-2 stimulates GH secretion independently of the GH-releasing hormone receptor. Endocrinology. 2005;146(9):3921–3929. (Jette L et al., 2005, Endocrinology — CJC-1295 pharmacokinetic characterisation in rats and primates)
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
  4. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223–253. (Foundational review of GHRH biology and GHRHR signalling)
  5. Johansen PB, Segev Y, Landau D, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in mouse models of Laron syndrome and untreated type 1 diabetes mellitus. FEBS Lett. 2003;553(1–2):35–38. (Contextual GH axis pharmacology)
  6. Walker RF. Sermorelin: A better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. (GHRH analogue context)

Disclaimer: This article is published for informational and scientific research purposes only. CJC-1295+DAC is sold by Pure Grade Labs strictly as a research chemical for laboratory use. It is not a licensed medicine and is not approved for human consumption, therapeutic use, or self-administration. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use. Dose ranges reported herein are cited directly from published peer-reviewed clinical trial literature and are presented solely to document what those trials examined under controlled conditions — they are not prescriptive recommendations. Individuals seeking guidance on any peptide or hormonal compound for personal use should consult a licensed medical professional. Pure Grade Labs complies with UK Human Medicines Regulations 2012 (HMR 2012). For research purposes only.